Elan Corporation, plc (ADR) (ELN), Perrigo Company (PRGO): Strange Biotech Bedfellows

Elan Corporation, plc (ADR) (NYSE:ELN)When I interviewed Alkermes Plc (NASDAQ:ALKS)‘ CEO Richard Pops last year, he described the relocation of the company’s headquarters to Ireland where taxes are lower after buying Elan Corporation, plc (ADR) (NYSE:ELN)‘s drug technology business as a “secondary feature of the transaction.” The extended-release technology, which complements Alkermes Plc (NASDAQ:ALKS)’ own platform, was what Alkermes Plc (NASDAQ:ALKS) was really after.

Fast forward to yesterday with the rest of Elan Corporation, plc (ADR) (NYSE:ELN) on the auction block, Perrigo Company (NYSE:PRGO) pulled the trigger for $16.50 in a cash plus stock deal. Unlike the Alkermes Plc (NASDAQ:ALKS)-Elan Corporation, plc (ADR) (NYSE:ELN) deal, Perrigo Company (NYSE:PRGO) – which sells generic over-the-counter medications, as well as some generic prescription drugs and pet medications — seems to have nothing in common with Elan Corporation, plc (ADR) (NYSE:ELN), which has essentially become a holding company for royalties from Biogen Idec Inc (NASDAQ:BIIB)‘s Tysabri after Elan Corporation, plc (ADR) (NYSE:ELN) spun off its research and development into Prothena Corporation PLC (NASDAQ:PRTA).

But there’s that tempting Ireland-based headquarters with its corporate tax of just 12.5%.

Perrigo Company (NYSE:PRGO) said it believes that the combined companies can save $150 million annually. Some of that will come from cutting salaries of the people left at Elan Corporation, plc (ADR) (NYSE:ELN), but much of it will come from tax savings from being located outside the U.S.

The new headquarters also gives Perrigo Company (NYSE:PRGO) a place to launch an international expansion. Moving into internal markets makes a lot of sense for generic drugs, where margins are much tighter than they are for branded drugs. Increasing scale can help expand margins since some costs are fixed. I’m not sure Perrigo Company (NYSE:PRGO) needed to buy a whole company just to get a global presence, but it’s certainly a shorter means to an end.

To justify the deal, Perrigo Company (NYSE:PRGO) needs more than just the Ireland headquarters. The royalties from Tysabri need to increase to justify the $8.6 billion price tag. You can go through the potential valuations, but I’m guessing that the fine folks at Royalty Pharma spent more time on it than you and I ever would and the fund was only willing to pay $15.50 per share, and that came with conditions of Tysabri reaching certain sales and development goals.

Admittedly, Royalty Pharma probably couldn’t get as much value (if any) from the Ireland headquarters as Perrigo can, but it certainly doesn’t look like Perrigo is getting a steal here.

Perrigo’s investors seem less than enthralled with the deal, sending shares down 7% yesterday. I really can’t blame them. The acquisition makes Perrigo more diversified, which can be a good thing, but in this case it also increases the risk. Perrigo is putting a lot of faith in what should be the primary feature of the transaction: Tysabri and Biogen Idec Inc (NASDAQ:BIIB)’s ability to continue increasing sales of the drug.

The article Strange Biotech Bedfellows originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Highest Grossing Musicals on Broadway

The Most Successful Reality TV Stars

Cheapest Cities to Visit in the US

Most Expensive Summer Camps

Most Expensive Animals in the World

Most Expensive Specialty Crops in the World

Movies That Took Ages to Make

The Longest Hollywood Films Ever Made

Most Expensive Concert Stages

The Richest Bands of all Time

10 Most Corrupt Countries 2013 List

10 Countries with the Highest Quality of Life Index

Most Expensive Mattresses in the World

5 Smallest Countries by Land Area

The Ultimate Heartbreak Songs

Richest Teenagers in the World

10 Most Haunted Places in America

10 Best Places to Retire in Florida East Coast

Top 10 Places to See Before You Die

Top 8 Countries in the World Where Justice Prevails

10 Richest States in America

15 Wealthiest Countries in the World

Richest Singers in the World

Most Expensive Tasting Menu in New York City

Most Expensive Baby Items in the World

Most Expensive Hotel Suites in Vegas

Most Expensive Brunch in New York City

Most Expensive Beef Cuts in the World

25 Best Colleges to Get a Job

Top 10 US Supermarkets

The 25 Most Dangerous Cities in the World to Visit

Most Expensive Xbox Games

Top 11 Cities Where Billionaires Live

Top 10 Most Charitable Companies in America

Most Expensive Seafood in the World

The 10 Wildest Conspiracy Theories

The 10 Best Job Markets in the US

Top 10 Accounting Scandals of All Time

The 25 Biggest Cities in the World

Top 10 Best Paying Virtual Jobs

Most Expensive Leather Shoes in the World

Top 6 Things to Buy in March

The 10 Most Stressful Jobs in America – 2014 List

Top 10 Jobs for Introverted People

Top 10 Honeymoon Destinations in the World

Top 10 Highest Paying Jobs in the World

Most Expensive Day-Care in New York City

The 10 Cheapest Places to Retire Abroad

Top 10 Most Expensive Luxury Cars in the World – 2014

Killer Small Business Ideas

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!